Clinical Trial Update: TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma [NA]

View source ↗

Summary

Clinical trial update on a combination of TQB2450, Anlotinib, and chemotherapy for gastric cancer and esophagogastric junction adenocarcinoma, which is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastric Junction
• Gastric Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | NA | Status: ACTIVE_NOT_RECRUITING